Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder

Simple item page
dc.contributor.authorManuel Gardea-Resendez
dc.contributor.authorMonica J. Taylor-Desir
dc.contributor.authorFrancisco Romo-Nava
dc.contributor.authorDavid Bond
dc.contributor.authorEric J. Vallender
dc.contributor.authorAlfredo B. Cuellar-Barboza
dc.contributor.authorMiguel L. Prieto
dc.contributor.authorNicolas Nunez
dc.contributor.authorMarin Veldic
dc.contributor.authorAysegul Ozerdem
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T16:25:45Z
dc.date.available2026-03-22T16:25:45Z
dc.date.issued2022
dc.descriptionCitaciones: 1
dc.description.abstractThis study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.
dc.identifier.doi10.1097/jcp.0000000000001532
dc.identifier.urihttps://doi.org/10.1097/jcp.0000000000001532
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/58184
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Psychopharmacology
dc.sourceMayo Clinic in Arizona
dc.subjectTardive dyskinesia
dc.subjectBipolar disorder
dc.subjectMedicine
dc.subjectMood stabilizer
dc.subjectMood
dc.subjectPsychiatry
dc.subjectBipolar illness
dc.subjectPhenotype
dc.subjectBioinformatics
dc.subjectTreatment of bipolar disorder
dc.titleClinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
dc.typearticle

Files

Collections

Artículo Científico Publicado